Enhanced antitumor immune response in melanoma tumor model by anti-PD-1 small interference RNA encapsulated in nanoliposomes
Author:
Funder
Mashhad University of Medical Sciences
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Molecular Biology,Molecular Medicine
Link
https://www.nature.com/articles/s41417-021-00367-9.pdf
Reference52 articles.
1. Mullen CA, Schreiber H. Tumor growth and evasion of immune destruction: UV-induced tumors as a model. Surv immunologic Res. 1985;4:264–70.
2. Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci USA. 2007;104:3967–72.
3. He X, Xu C. PD-1: a driver or passenger of T cell exhaustion? Mol Cell. 2020;77:930–1.
4. Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018;6:8.
5. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994;1:405–13.
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Advancing cancer immunotherapy through siRNA-based gene silencing for immune checkpoint blockade;Advanced Drug Delivery Reviews;2024-06
2. Liposome-based nanomedicine for immune checkpoint blocking therapy and combinatory cancer therapy;International Journal of Pharmaceutics;2024-03
3. A landscape of recent advances in lipid nanoparticles and their translational potential for the treatment of solid tumors;Bioengineering & Translational Medicine;2023-11-09
4. Advances in PD-1 signaling inhibition-based nano-delivery systems for tumor therapy;Journal of Nanobiotechnology;2023-07-04
5. Immune checkpoint inhibition mediated with liposomal nanomedicine for cancer therapy;Military Medical Research;2023-04-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3